BNF:

4.7.2

Status:

Grey, Red, Green

Decision Date:

October 2022

Comments

GREEN:

• Twice daily MR preparations. MR preparations to be prescribed by brand (Zomorph most cost effective).
• Oral solution 10mg/5ml (Oramorph brand most cost-effective)

GREY: Once daily MR preparation - MXL. Reserved for use when twice daily MR preparations are not appropriate. (Decision date - March 2018)  

GREY: Morphine orodispersible - For exceptional use where risk assessment indicates. (Decision date - August/October 2022)

• risk of harm to self or through confusion
• chronic pain and at risk of intentional overdose (e.g. depression, EUPD)
• pain/palliative care and at risk of unintentional overdose (dementia, Alzheimer’s)
• additional patient factors e.g. poor manual dexterity

RED: Morphine 100microg/ml oral solution and Morphine 500microg/ml oral solution - For Neonatal abstinence syndrome (NAS). (Decision date - March 2024)

Grey Drug Classifications

• 4: Lack of data on cost-effectiveness compared with standard therapy
• 5: Less cost-effective than current standard therapy

search again